Member Info for init2oneit

The potential is there.

GSK in patient data deal with American AI specialist to boost medicines pipeline

https://www.thetimes.co.uk/article/53237c04-4eee-11ed-b120-ca4f3ffbcdc5?shareToken=3d01df878bf046847ecfe4bdd0937c4a

We should get some update from the Co by some medium in the near future.

Sorry for mixing website.A very similar name im very similar business. I wasn’t paying proper attention.

Sorry forget that very similar name

It came up briefly. Looks like still in development

https://dev.arctoris.com/

Wonder what plays lay ahead for the renamed Co.

Check Companies House …. We have a new name

After all, whilst one division was heavily loss making, one division had a £22m profit with a NAV of £80 odd million. Then of course we have the loan note debt to consider and it looks like conversion into shares may take place in January depending on the holders of these loan notes That’s when the dilution occurs

I would suggest this Co under Alex Snow may have undergone / still undergoing rapid reorganisation. We know the board, now only consists of 4 and some senior management positions have also been axed. With Concentration on RWD, a completely revamped Co could emerge, worthy of a sale at a good price when the time is right.

Last year.

https://gatemore.com/wp-content/uploads/2021/07/Gatemore-Letter-to-Sensyne.pdf

Since then a lot has changed.

I think you will find that is some ‘do good’ protest type organisation focused on ‘human rights’. We will see if Sensyne can carry the NHS with it. There is still a lot to ‘win’ here. It cannot be too long before we see the year end April 22 results published on Companies House website and perhaps some encouraging news on progress since Alex Snow has taken over. There is already some details with a statement from an August board meeting on cash status and divestment proceedings within the accounts for the divisions published at Companies House.

That research was submitted here on 2nd https://arxiv.org/abs/2208.01607

Page 21 ‘acknowledgments’

A big research project released in August between Sensyne and Bayer. Also by the way there are a number of Sensyne employees working remotely from Germany from their LinkedIn info.
https://arxiv.org/pdf/2208.01607.pdf

Does this bode well for future collaboration?

If you read through the info already published with the divisions accounts already lodged with Companies House, an AGM is due. This note can be found with the info re Grant Thornton to continue as accountants and to ‘voted at upcoming AGM’ Hopefully we might have the date once the whole group accounts are published for the period ending April 22. The AGM may offer Snow the possibility of updating shareholders on progress since he took over.

https://www.prnewswire.co.uk/news-releases/gatemore-capital-management-presents-sensyne-health-at-13d-monitor-870214240.html

From the info available from ‘about the Co ‘ in the ‘vacancies’ section of the Co website, seems they are growing the Real World Evidence team. All part of Snow’s realignment of the Co ? If so, there would indeed appear to be, som optimism for the future.

Some info on RWE here.

https://www.arbormetrix.com/blog/9-ways-real-world-evidence-is-changing-healthcare

Also looks like they may have changed their HR system with Bamboo HR now powering this department of the Co.

Looks like someone from the Co has been looking here ?? both Hudson and Tarassenko now removed from website as Co directors.

A good read reported in April

Article

https://www.thetimes.co.uk/article/e19c97a6-b752-11ec-8c29-375fe0cc1f19?shareToken=b6bbc8bfb5aa39bbcbeac4725d97cd63